Literature DB >> 28211810

Therapeutics of Neurotransmitters in Alzheimer's Disease.

Ramesh Kandimalla1,2, P Hemachandra Reddy1,2,3,4,5.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the loss of memory, multiple cognitive impairments and changes in the personality and behavior. Several decades of intense research have revealed that multiple cellular changes are involved in disease process, including synaptic damage, mitochondrial abnormalities and inflammatory responses, in addition to formation and accumulation of amyloid-β (Aβ) and phosphorylated tau. Although tremendous progress has been made in understanding the impact of neurotransmitters in the progression and pathogenesis of AD, we still do not have a drug molecule associated with neurotransmitter(s) that can delay disease process in elderly individuals and/or restore cognitive functions in AD patients. The purpose of our article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD. We also updated the current status of clinical trials using neurotransmitters' agonists/antagonists in AD.

Entities:  

Keywords:  Acetylcholine inhibitors; Alzheimer’s disease; N-methyl-D-aspartate; adenosine receptors; histaminergic; neurotransmitters

Mesh:

Substances:

Year:  2017        PMID: 28211810      PMCID: PMC5793221          DOI: 10.3233/JAD-161118

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  204 in total

Review 1.  The glutamate receptor ion channels.

Authors:  R Dingledine; K Borges; D Bowie; S F Traynelis
Journal:  Pharmacol Rev       Date:  1999-03       Impact factor: 25.468

2.  Neuronal histamine deficit in Alzheimer's disease.

Authors:  P Panula; J Rinne; K Kuokkanen; K S Eriksson; T Sallmen; H Kalimo; M Relja
Journal:  Neuroscience       Date:  1998-02       Impact factor: 3.590

3.  Metabotropic and ionotropic glutamate receptors mediate the modulation of acetylcholine release at the frog neuromuscular junction.

Authors:  Andrei Tsentsevitsky; Leniz Nurullin; Evgeny Nikolsky; Artem Malomouzh
Journal:  J Neurosci Res       Date:  2016-10-22       Impact factor: 4.164

Review 4.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 5.  Mechanisms of excitotoxicity in neurologic diseases.

Authors:  M F Beal
Journal:  FASEB J       Date:  1992-12       Impact factor: 5.191

Review 6.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

Review 7.  Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2015-12-17

Review 8.  Understanding Aspects of Aluminum Exposure in Alzheimer's Disease Development.

Authors:  Ramesh Kandimalla; Jayalakshmi Vallamkondu; Edwin B Corgiat; Kiran Dip Gill
Journal:  Brain Pathol       Date:  2015-12-08       Impact factor: 6.508

9.  Molecular mechanisms underlying memory consolidation of taste information in the cortex.

Authors:  Shunit Gal-Ben-Ari; Kobi Rosenblum
Journal:  Front Behav Neurosci       Date:  2012-01-05       Impact factor: 3.558

Review 10.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911

View more
  54 in total

1.  A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease.

Authors:  P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 2.  The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors:  Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal:  Neuromolecular Med       Date:  2019-01-17       Impact factor: 3.843

3.  Soursop fruit extract mitigates scopolamine-induced amnesia and oxidative stress via activating cholinergic and Nrf2/HO-1 pathways.

Authors:  Naif E Al Omairi; Ashraf Y Al-Brakati; Rami B Kassab; Maha S Lokman; Ehab Kotb Elmahallawy; Hatem K Amin; Ahmed E Abdel Moneim
Journal:  Metab Brain Dis       Date:  2019-03-27       Impact factor: 3.584

4.  Investigation of therapeutic potential of cerium oxide nanoparticles in Alzheimer's disease using transgenic Drosophila.

Authors:  Vignesh Sundararajan; G Devanand Venkatasubbu; Sahabudeen Sheik Mohideen
Journal:  3 Biotech       Date:  2021-03-06       Impact factor: 2.406

5.  Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer's disease.

Authors:  Julie C Lauterborn; Pietro Scaduto; Conor D Cox; Anton Schulmann; Gary Lynch; Christine M Gall; C Dirk Keene; Agenor Limon
Journal:  Nat Commun       Date:  2021-05-10       Impact factor: 14.919

6.  Screening for Core Genes Related to Pathogenesis of Alzheimer's Disease.

Authors:  Longxiu Yang; Yuan Qin; Chongdong Jian
Journal:  Front Cell Dev Biol       Date:  2021-04-22

7.  Biocomputational Screening of Natural Compounds against Acetylcholinesterase.

Authors:  Syed Sayeed Ahmad; Mohd Babu Khan; Khurshid Ahmad; Jeong-Ho Lim; Sibhghatulla Shaikh; Eun-Ju Lee; Inho Choi
Journal:  Molecules       Date:  2021-04-30       Impact factor: 4.411

8.  Protective effect of andrographolide against STZ induced Alzheimer's disease in experimental rats: possible neuromodulation and Aβ(1-42) analysis.

Authors:  Royal Patel; Karamjeet Kaur; Shamsher Singh
Journal:  Inflammopharmacology       Date:  2021-07-07       Impact factor: 4.473

9.  Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease.

Authors:  Arubala P Reddy; Xiangling Yin; Neha Sawant; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-05-29       Impact factor: 6.150

Review 10.  Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer's Disease.

Authors:  Lei Zhang; Zhipeng Qi; Jiashuo Li; Minghui Li; Xianchao Du; Shuang Wang; Guoyu Zhou; Bin Xu; Wei Liu; Shuhua Xi; Zhaofa Xu; Yu Deng
Journal:  Mol Neurobiol       Date:  2021-03-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.